Sequoia Capital recently announced major changes including closing its London office and merging teams, which some see as undoing former leader Roelof Botha's legacy. The tension escalated when Botha joined SpaceX's board without informing Sequoia partners, surprising them due to potential conflicts with the firm's $20 billion stake in SpaceX. This move deepened the rift between Botha and Sequoia, though the firm says it continues to collaborate with him. The situation highlights internal disagreements over leadership style and strategic direction at Sequoia.
Sequoia Capital's internal board tensions provide context for readers following the story. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Nov 09, 2026 02:31 WIB: out of 150 priced stocks, 80 rose and 68 fell. Notable movers include Workiva Inc (WK) at USD 72.76 with a 1-day change of -14.82%, Bitdeer Technologies Group (BTDR) at USD 6.01 with +13.28%, and Quantum Computing Inc (QUBT) at USD 6.33 with +12.43%.
NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
